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Background: Progressive supranuclear palsy (PSP) is a neurodegenerative disorder pathologically characterized by
intracellular tangles of hyperphosphorylated tau protein distributed throughout the neocortex, basal ganglia, and
brainstem. A genome-wide association study identified EIF2AK3 as a risk factor for PSP. EIF2AK3 encodes PERK, part
of the endoplasmic reticulum’s (ER) unfolded protein response (UPR). PERK is an ER membrane protein that senses
unfolded protein accumulation within the ER lumen. Recently, several groups noted UPR activation in Alzheimer’s
disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis, multiple system atrophy, and in the
hippocampus and substantia nigra of PSP subjects. Here, we evaluate UPR PERK activation in the pons, medulla,
midbrain, hippocampus, frontal cortex and cerebellum in subjects with PSP, AD, and in normal controls.
Results: We found UPR activation primarily in disease-affected brain regions in both disorders. In PSP, the UPR was
primarily activated in the pons and medulla and to a much lesser extent in the hippocampus. In AD, the UPR was
extensively activated in the hippocampus. We also observed UPR activation in the hippocampus of some elderly
normal controls, severity of which positively correlated with both age and tau pathology but not with Aβ plaque
burden. Finally, we evaluated EIF2AK3 coding variants that influence PERK activation. We show that a haplotype
associated with increased PERK activation is genetically associated with increased PSP risk.
Conclusions: The UPR is activated in disease affected regions in PSP and the genetic evidence shows that this
activation increases risk for PSP and is not a protective response.
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Progressive supranuclear palsy (PSP) is a late-onset neu-
rodegenerative movement disorder clinically characterized
by vertical gaze palsy, poor balance and frequent falls, as
well as cognitive impairment and dementia [1,2]. The pri-
mary symptoms of PSP are consistent with the observed
neuropathology, mainly neuronal degeneration in the
brainstem, particularly the pons and medulla [3]. Postmor-
tem pathological analysis of these brain regions in PSP pa-
tients reveals numerous intracellular neurofibrillary and* Correspondence: gerardsc@mail.med.upenn.edu
1Department of Pathology and Laboratory Medicine, 3630 Hamilton Walk.
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
19104, USA
8607 Stellar Chance Laboratories, 422 Curie Blvd, Philadelphia, PA 19104, USA
Full list of author information is available at the end of the article
© 2013 Stutzbach et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the orglial tangles comprised of hyperphosphorylated protein
tau (htau). Thus PSP, along with Alzheimer’s disease (AD),
belongs to a group of disorders collectively known as
tauopathies, as all these disorders show abundant tau ag-
gregates or inclusions as prominent neuropathologic fea-
tures. Other tauopathies include frontotemporal dementia
with Parkinsonism linked to chromosome 17 (FTDP-17),
corticobasal degeneration (CBD), and Pick’s disease [4].
Some mutations in the gene MAPT, which encodes tau,
can result in a PSP phenotype [5-9], while common vari-
ants in the MAPT region are associated with PSP suscepti-
bility [10-13]. Thus, genetic studies as well as our data
here indicate that tau is clearly linked to PSP pathogenesis.
Schellenberg and colleagues recently completed a
genome-wide association study (GWAS) for PSP risk lociral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion initiation factor 2 alpha kinase 3 (EIF2AK3), which
encodes the protein pancreatic endoplasmic reticulum
kinase (PERK). PERK is an endoplasmic reticulum (ER)
membrane protein that acts as a stress sensor in the ER
unfolded protein response (UPR). In addition to PERK,
there are two other stress sensors (both of which are also
ER membrane proteins): inositol-requiring enzyme 1α
(IRE1α) and activating transcription factor 6 (ATF6; [14]).
All three arms of the UPR activate when the chaperone
immunoglobulin binding protein (BiP), normally bound on
the luminal side of each protein, dissociates in order to aid
in the folding of accumulated unfolded proteins in the ER
lumen. Dissociation of BiP from PERK and IRE1α fa-
cilitates their activation by promoting homodimerization
and trans-autophosphorylation [15]. ATF6 is then activated
via a cleavage event and subsequently translocated from
the ER to the nucleus [16]. Each of the three branches of
the UPR initiates discrete signaling cascades in response to
the accumulation of unfolded proteins in the ER lumen.
The role of the UPR is to restore protein homeostasis by
upregulating chaperone production [17,18], attenuating
translation, promoting degradation of misfolded proteins
via ER-associated degradation (ERAD; [19], and promoting
autophagy [20]. Prolonged ER stress can trigger apoptosis
[14,21].
The PERK arm of the UPR acts primarily on translation.
When PERK is activated (thus becoming phosphorylated
PERK, or pPERK), a kinase domain on the cytosolic side
of the protein phosphorylates eukaryotic translation initi-
ation factor 2α (eIF2α or peIF2α when phosphorylated).
peIF2α is a less active form of the protein, and its de-
creased efficiency slows general translation initiation and
promotes translation of activating transcription factor 4
(ATF4). ATF4 promotes transcription of genes that en-
hance amino acid uptake and protect against oxidative
stress [22]. Elements of the PERK pathway are also in-
volved in regulating autophagy, a process that degrades
misfolded proteins [23,24]. Thus, genetic variation that re-
sults either in alteration of PERK protein function or sig-
nificant changes in the amount of PERK would perturb
several crucial stress-response pathways.
Several neurodegenerative disorders, including PSP, are
characterized by pathological aggregates of misfolded pro-
teins in the brain. Previous work showed that the UPR is
activated in post-mortem AD brains [25], as well as in the
brains of patients with frontotemporal lobar degeneration
with tau inclusions (FTLD-tau) [26], PD [27], amyotrophic
lateral sclerosis (ALS) [28,29], and multiple system atro-
phy (MSA) [30]. Nijholt et al. (2011) reported evidence of
UPR activation in the hippocampus and, to a lesser extent,
the locus coeruleus and putamen of PSP patients.
We investigated activation of PERK and eIF2α in post-
mortem brains from subjects with PSP and AD, as wellas from normal elderly subjects. We used antibodies that
recognize the phosphorylated species of PERK and eIF2α,
i.e. the activated forms of these 2 proteins (pPERK and
peIF2α, respectively). Our primary goal was to investigate
the brain regions most affected by tau pathology in PSP.
We searched for evidence of PERK and eIF2α activation
in the pons, medulla and midbrain, regions affected in
PSP, in the hippocampus and frontal cortex, which are re-
gions affected in AD, and in the cerebellum, a brain region
which is relatively spared in both diseases, although the
deep cerebellar nuclei and cerebellar cortex may harbor
modest amounts of tangles and plaques, in PSP and AD,
respectively. We also looked at PERK and eIF2α activation
in young controls to determine if ER stress is activated in
normal aging. Our results indicated that PERK and eIF2α
activation parallels the pattern of neuropathology in PSP
and AD. In normal hippocampus, activation increases
with age and correlates with tau but not Aβ amyloid path-
ology. We also examined coding haplotypes that were pre-
viously shown to affect PERK activation [31]. We found
that the haplotype that corresponding to the highest PERK
activation is in linkage disequilibrium (LD) with the high
risk allele of the top PSP GWAS marker, indicating that
UPR activation increases PSP risk and is not a protective
response in PSP.
Results
The PERK arm of the UPR is activated in PSP
To determine whether the UPR is activated in PSP, we
stained post-mortem human brain tissue from PSP and AD
patients as well as normal elderly controls using antibodies
against pPERK and peIF2α, the activated forms of these
proteins. We chose six brain areas to stain for PERK and
eIF2α activation: the pons, medulla, and midbrain (affected
in PSP), the hippocampus and frontal cortex (affected in
AD), and the cerebellum, which is relatively spared in both
diseases.
In PSP cases, of the regions tested, the pons, medulla,
and midbrain demonstrated the highest degree of pPERK
and peIF2α staining (Figures 1b, 2b, 3a-c, and 4a-c) as
measured by number of cells showing staining per field
(Additional file 1: Figure S1). These are the brain areas
most affected by tau pathology in PSP. pPERK and peIF2α
staining was punctate and cytoplasmic with some non-
specific nuclear staining (Figures 1a and 2a), a pattern ob-
served by others in AD and PD [25,27]. In the pons, all
PSP cases showed some cells positive for both pPERK and
peIF2α. pPERK was observed in the medulla and midbrain
in all but one case for each region. For peIF2α, all cases
showed positive cells in the medulla and all but one case
showed positive cells in the midbrain.
PSP cases as a group showed significantly more pPERK
and peIF2α staining in the pons, medulla, and midbrain
compared to elderly controls. For pPERK, only one control
Figure 1 pPERK is activated in PSP, AD, and normal brain.
a. Example of a cell with pPERK immunoreactive puncta in the pons
of a PSP case. b-d. Representative fields showing pPERK staining of
pons, hippocampus, and cerebellum in normal, PSP, and AD cases.
Scale bars are 50 μm unless otherwise indicated.
Figure 2 peIF2α is activated in PSP, AD, and normal brain.
a. Example of a cell with peIF2α puncta in the pons of a PSP case.
b-d. Representative fields from peIF2α staining of pons,
hippocampus, and cerebellum in normal, PSP and AD cases. Scale
bars are 50 μm unless otherwise indicated.
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and medulla. This is not the same control subject that
displayed Lewy body pathology in the medulla. In the mid-
brain, very few controls were positive for pPERK. For
peIF2α, most controls were negative in these brain areas ex-
cept for a single subject with rare positive cells in the me-
dulla. For AD, there were more positive cases with a higher
density of positive cells compared to controls but less than
found in PSP (Figures 3 and 4a-c, Table 1).
In the hippocampus and frontal cortex, AD cases as a
group scored significantly higher than PSP or normal eld-
erly controls for both pPERK and peIF2α staining (Table 1).
pPERK and peIF2α staining was especially strong in the AD
hippocampus, with nearly all cases demonstrating high
levels of positive cells. All PSP cases had mild to moderate
pPERK staining in the hippocampus, though not all cases
demonstrated peIF2α staining. Surprisingly, many normal
elderly controls demonstrated at least a mild level of
pPERK and peIF2α positive cells in the hippocampus (Fig-
ures 1c, 2c, 3d, and 4d). Staining was generally milder in
the frontal cortex than in the hippocampus, although AD
cases still scored significantly higher than PSP cases or nor-
mal controls (Figures 3e and 4e). PSP cases scored signifi-
cantly higher than normal controls for pPERK staining but
not for peIF2α staining (Table 1). Notably, the pons, me-
dulla, and midbrain are severely affected in PSP [2] but only
moderately or mildly affected in AD [32]. Conversely, thehippocampus and frontal cortex are strongly affected in AD
[32], but only mildly affected or unaffected in PSP. Thus,
PERK activation is strongest in areas of the brain highly af-
fected by pathology in PSP and AD. Nearly all cases were
negative for pPERK and peIF2α in the folia of the cerebel-
lum (Figures 1d, 2d, 3f, and 4f), although one AD case
showed rare staining in this area, but, in general, there is lit-
tle to no pathology in this area in PSP or AD, and thus our
findings are consistent with the inference that pathology
and PERK activation occur in the same disease-affected
brain areas.
Activation of pPERK in htau positive cells
We were interested in whether the UPR is activated
in cells affected by tau pathology. We performed
double immunofluorescence staining for pPERK and
htau on sections of pons and hippocampus in PSP,
AD, and normal controls (Figure 5a). In PSP pons, an
average of 72% of pPERK positive cells were also
positive for htau. However, only 43% of htau positive
cells were also positive for pPERK (Figure 3c). This
substantial overlap is in contrast to AD hippocampus,
in which only 20% of pPERK positive cells also
stained for htau and only 12% of htau positive cells
stained for pPERK (Figure 3d). Overlap between htau
and pPERK staining was also low in PSP and normal
hippocampus (data not shown). In the pons, overlap
between pPERK puncta and htau occurred mostly in
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Figure 3 Frequency of pPERK staining scores in PSP, AD, and normal brain. Distribution of pPERK staining scores. +++ = widespread
activation, ++ =moderate activation, + = diffuse activation, R = rare activation, - = no activation. Y-axis indicates number of cases with a particular
pPERK staining score. All P-values obtained using Fisher exact test. a-c. PSP cases had the strongest pPERK staining in the pons (PSP vs. Normal:
p = 3.8E-9) and the medulla (PSP vs. Normal: p = 6.1E-7), as well as moderate staining in the midbrain (PSP vs. Normal: p = 6.0E-6) which was
affected in all PSP cases. d-e. AD cases had the strongest pPERK staining in the hippocampus (AD vs. Normal: p = 0.0006) and moderate staining
in the frontal cortex (AD vs. Normal: p = 4.1E-5) both of which were affected in AD. f. No cases had significant pPERK staining in the cerebellum.
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than dense, fibrillar staining (Figure 3b). This suggests
that PERK is activated in pre-tangle neurons. Hoozemans
et al. [25] described similar distribution of htau/pPERK
staining in AD hippocampus.PERK is activated in normal hippocampus
Une xpectedly, we found pPERK and peIF2α staining in
the hippocampus of age-matched elderly normal con-
trols as described above. To follow up on this finding,
we expanded our initial control hippocampus sample to
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Figure 4 Frequency of peIF2α staining scores in PSP, AD, and normal brain. Distribution of peIF2α staining scores. +++ =widespread
activation, ++ =moderate activation, + = diffuse activation, R = rare activation, - = no activation. Y-axis indicates number of cases with a particular
peIF2α staining score. All P-values obtained using Fisher exact test. a-c. PSP cases had the strongest peIF2α staining in the pons (PSP vs. Normal:
p = 4.1E-5) and the medulla (PSP vs. Normal: p = 6.0E-6), as well as moderate staining in the midbrain (PSP vs. Normal: p = 0.00041) which was
affected in all PSP cases. d-e. AD cases had the strongest peIF2α staining in the hippocampus (AD vs. Normal: p = 0.0042) and moderate staining
in the frontal cortex (AD vs. Normal: p = 4.1E-5) both of which were affected in AD. f. No cases had significant peIF2α staining in the cerebellum.
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mean: 52.4; see Additional file 1: Table S1). We found
that age significantly correlated with the pPERK staining
score (Figure 6a). The older the subject, the more likely
they were to have high levels of PERK activation in the
hippocampus. However, not all aged normal controls
demonstrated hippocampal pPERK activation although
some subjects at all ages examined here were negative
for pPERK staining.We also found that the level of tau pathology corre-
lated with pPERK staining. The more tau pathology (as
measured by PHF-1 staining) in a normal hippocampus,
the more likely that the hippocampus was also positive
for activated PERK (Figure 6b). All controls negative for
pPERK staining were also negative for htau staining; cases
with severe pPERK staining scores also scored high for
htau. This correlation was significant (Spearman R: 0.7523,
p = .0002). There was no correlation between pPERK
Table 1 P-values for comparison of pPERK and pEIF2α immunoreactivity in PSP, AD, and normal controls for different
brain regions
Comparison
groups
Pons Medulla Midbrain Hippocampus Frontal cortex Cerebellum
pPERK peIF2α pPERK peIF2α pPERK peIF2α pPERK peIF2α pPERK peIF2α pPERK peIF2α
AD vs. Normal 3.4E-5 0.0045 0.034 0.041 0.0026 0.0037 0.0006 0.0042 4.1E-5 4.1E-5 0.4 1
PSP vs. AD 3.8E-4 0.00049 1.7E-4 0.028 4.0E-7 0.009 0.000021 8.2E-5 1.6E-4 0.0049 0.5 1
PSP vs. Normal 3.8E-9 4.1E-5 6.1E-7 6.0E-6 6.0E-6 1.4E-4 0.0034 0.073 0.0045 0.1 1 1
P-values are from a Fisher exact test. “E” indicates “x 10^”. pPERK and peIF2α staining in PSP brainstem areas (pons, medulla, midbrain) were significantly greater
than in AD or normal brainstem areas. AD brainstem areas had significantly more pPERK and peIF2α staining than normal brainstem areas. In contrast, primary
AD-affected brain areas (hippocampus, frontal cortex) had significantly more pPERK and peIF2α staining than PSP or normal hippocampus and frontal cortex.
There was no difference in staining between AD, PSP, or normal brains in the cerebellum.
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ology (as measured by Thioflavin S staining to detect senile
plaques); all normals with high pPERK scores and relatively
high tau scores in the hippocampus were negative for Aβ
amyloid plaques and Lewy bodies (data not shown). h
ip
p
o
ca
m
p
u
s +++ 
++ 
aPERK protein coding variants are associated with PSP risk
Alleles at rs7571971 are significantly associated with PSP
risk [10]. To identify other SNPs in high linkage disequi-
librium with rs7571971, we evaluated 1000 Genomes
data for subjects of European ancestry. As assessed by
LD measure r2 [34], 14 SNPs were in high LD with
rs7571971 (r2 > 0.8), including the 3 non-synonymous
coding variants. Of these 14, none fell in the coding re-
gion of any gene besides EIF2AK3 and all but 5 fell
within EIF2AK3 (Table 2).Figure 5 Hyperphosphorylated tau and pPERK partially
co-localize in PSP pons and AD hippocampus. a. Example of a
neuron co-stained for htau (red) and pPERK (green). Tau staining is
widespread and diffuse. pPERK staining is punctate and localized to the
soma and proximal neurites. b. pPERK staining occurred mostly in cells
with diffuse, non-fibrillar htau staining. Cells with dense, fibrillar htau
staining did not stain for activated PERK (*). c. In PSP pons, most pPERK
positive cells also stained for htau (72%), whereas fewer than half of htau
stained cells (43%) also stained positive for pPERK. d. htau and pPERK
staining overlapped very little in AD hippocampus (14% and 20%). Scale
bars are 50 μm unless otherwise indicated.The 3 non-synonymous coding variants in EIF2AK3
were Ser136Cys, Arg166Gln, and Ser704Ala. When hap-
lotypes were constructed from 1000 Genome data, there
were two common haplotypes (Table 3): Ser-Arg-Ser
(haplotype A) and Cys-Gln-Ala (haplotype B) with pre-
dicted frequencies of 0.64 and 0.29, respectively; one un-
common haplotype, Ser-Gln-Ser (haplotype D), with a
frequency of 0.06; and 4 rare haplotypes of frequency
close to 1/1000. The top PSP GWAS SNP for this gene
is rs7571971, a 2-allele polymorphism in EIF2AK3 intron0 10 20 30 40 50 60 70 80 90 100
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Figure 6 Severity of PERK activation in normal hippocampus
correlates with age and tau pathology. a. Plot of pPERK staining score
(X-axis) versus subject age at death (Y-axis). Each diamond represents
one normal subject. Some individuals both young and old were
negative for pPERK staining. Of those that stained positive for pPERK
(including those showing rare through +++ levels of immunoreactivity),
older individuals tended to have more severe pPERK staining scores.
b. Frequency table plotting htau score against pPERK staining score in
normal hippocampus. Htau score and pPERK score were positively
correlated (Spearman R: .7523; p = 0.0002). The higher the htau score of
an individual hippocampus, the higher the pPERK staining score tended
to be. Htau scores were obtained from the CNDR Integrated
Neurodegenerative Disease Database [33] using antibody PHF-1.
Table 2 SNPs in high LD with rs7571971
SNP Gene Distance in base pairs
from GWAS hit SNP
RSquared DPrime Coordinate_HG18
rs1805165 EIF2AK3 20460 0.889 1 88656006
rs6739095 EIF2AK3 15287 0.886 0.96 88661179
rs11898161 EIF2AK3 13703 0.925 1 88662763
rs1913671 EIF2AK3 4532 0.886 0.96 88680998
rs11681299 EIF2AK3 6381 0.889 1 88682847
rs867529 EIF2AK3 17922 0.889 1 88694388
rs6731022 EIF2AK3 21684 0.886 0.96 88698150
rs11684404 EIF2AK3 29271 0.886 0.96 88705737
rs11680549 EIF2AK3 30997 0.813 0.957 88707463
rs6547787 34385 0.886 0.96 88710851
rs1606803 37965 0.889 1 88714431
rs62157778 38739 0.889 1 88715205
rs13003510 46139 0.925 1 88722605
rs13001657 51260 0.888 0.96 88727726
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Figure 7 Comparison of PERK haplotype with GWAS risk allele.
A GWAS for PSP identified a risk locus on chromosome 2
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1000 genome analysis, the minor allele for rs7571971 is al-
most perfectly correlated with haplotype B and the major
allele with haplotypes A and D.
To confirm the relationship of LD amongst SNP alleles
in PSP subjects, we genotyped 1,043 PSP cases for
rs7571971, and the 3 coding variant SNPs. The genotypes
for these four SNPs were then phased using maximum
likelihood. We observed that, in PSP cases, haplotype fre-
quencies were almost identical to those from 1000 Ge-
nomes data: for A, 0.645 versus 0.642; for B, 0.288 versus
0.301; and for D, 0.061 versus 0.053. Again haplotypes A
and D are completely correlated with rs7571971 allele C
(Figure 7), the protective PSP allele. Haplotype B is com-
pletely correlated with allele T, the high risk PSP allele. Re-
cently Liu et al. [31] showed that when lymphoblastoid cell
lines are treated with thapsigarin to induce ER stress, cells
homozygous for the B haplotype showed stronger activa-
tion than cells homozygous for the A haplotype. Thus B is
the high-risk haplotype for PSP suggesting that activation is
not a protective response, but rather increases risk for PSP.
Discussion
We found that PERK is activated in disease-affected brain
regions in PSP, including the pons, medulla, and midbrain.Table 3 PERK haplotypes
rs867529-
rs13045-
rs1805165
Affected amino
acids
Alleles (%)
PSP (n = 994)
Haplotype A GCA Ser136-Arg166-Ser704 1233 (62.5)
Haplotype B CTC Cys136-Gln166-Ala704 626 (31.7)
Haplotype D GTA Ser136-Gln166-Ser704 113 (5.7)We also found that PERK’s downstream effector, eIF2α,
is activated similarly in PSP brainstem areas. In contrast,
PERK and eIF2 are not activated or only weakly activated
in normal and AD brainstem, respectively. We confirmed
that AD cases have strong immunoreactivity for pPERK
and peIF2α in the pyramidal cells of the hippocampus [25]
and in the frontal cortex. In contrast, PSP cases show mild
to moderate pPERK staining in these regions [26]. PERK
and eIF2α were not activated in the cerebellum in either(rs7571971). The common, low risk allele at this locus is cytosine
(C) and the PSP risk allele is thymine (T) [10]. Among individuals
homozygous for C at this locus, all harbor PERK haplotype A or D in
some combination. Individuals heterozygous (C/T) at this locus were
heterozygous for haplotypes A, B, and/or D. Individuals homozygous
for T at the GWAS risk locus were always homozygous for PERK
haplotype B. This demonstrates that one of the two amino acid
changes conferred by the B PERK haplotype that are not shared by
the D haplotype may be responsible for the PSP risk evident on Chr. 2.
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allels the regional distribution of pathology in these two
disorders.
We explored the relationship between abnormal tau
deposits and UPR activation in the PSP brainstem. Al-
though there is some overlap between cells with activated
PERK and cells with htau, at least half of htau-positive
cells do not have concurrent PERK activation. A greater
proportion of pPERK positive cells were also positive for
tau, but 25% stained for pPERK alone. Thus, although
PERK is activated in brain regions highly affected by tau
pathology, htau and pPERK do not necessarily overlap at
the single cell level. One potential explanation for lack of
complete overlap may be that PERK activation precedes
tangle formation, and is no longer activated in cells with
mature tangles. We found that overlap between pPERK
and htau mostly occurred in cells with diffuse htau stain-
ing rather than dense tau staining, supporting this hypoth-
esis. Similarly, Hoozemans et al. (2009) found that cells in
the AD hippocampus that were positive for pPERK also
stained for markers of early tau aggregation [25]. This
evidence suggests that PERK activation may temporally
precede overt tau aggregation, and could be triggered by
immunohistochemically undetectable levels of abnormal
tau. The genetic data implicating both PERK and tau in
PSP supports a plausible temporal relationship between
PERK activation and tau aggregation.
Genetic findings [10] and the data presented here im-
plicate PERK as well as the UPR in the pathogenesis of
PSP. Genetic findings also associate MAPT with PSP
[7,10,35,36], and along with the presence of aggregated
tau as the key neuropathologic feature of PSP, these data
clearly establish that tau is intimately linked to PSP
pathogenesis. While the UPR is activated by misfolded
proteins within the ER, and aggregated misfolded tau oc-
curs in PSP, AD, and other tauopathies, tau is a cytosolic
protein and does not appear to traffic through the ER as
part of a secretory pathway. In normal neurons, most
tau protein is intracellular and attached to microtubules.
In tauopathies, tau aggregates in the cytoplasm of cells,
in cellular processes, and at nerve terminals, but there is
no evidence that tau aggregates in the ER. Recent work
in mouse models of α-synucleinopathies [37,38] and
studies on PD autopsy material [38] suggest that small
amounts of α-synuclein can be found in ER, and that in
the disease state, these levels are elevated, thereby acti-
vating the ER stress response. Still, since there is no direct
evidence that tau traffics through the ER, or evidence of
tau aggregates in the ER, it is unlikely that misfolded tau
directly activates the canonical UPR. This view is sup-
ported by the fact that in PSP, pPERK and pEIF2α are acti-
vated in cells with no observable tau pathology, but we
cannot exclude the possibility that very low or undetectable
levels of aggregated tau are present. Rather, a more likelyexplanation is that tau-induced cytoplasmic events act to
trigger the UPR by an unknown mechanism, which in turn
influences the degradation of tau. A possible mechanism is
that cytoplasmic aggregated tau may inhibit processes such
as the ERAD-proteosome pathway used by cells to degrade
misfolded ER proteins, and thus preventing the normal
degradation of these proteins, stimulating ER stress [39].
PERK and eIF2α are also activated in pathology-
associated regions of a number of other neurodegenera-
tive diseases, including another tauopathy, AD [25]. The
UPR is also activated in non-tau diseases that include
ALS where UPR activation is observed in the spinal cord
in sporadic cases [28], and in PD where UPR activation
occurs in the substantia nigra [27]. Expanded-repeat
huntingtin, the pathological protein in Huntington’s dis-
ease, induces ER stress in culture [40]. Notably, these
diseases share a common pathology, i.e. the accumula-
tion of abnormal aggregated proteins in the CNS. Thus,
there may be a common mechanism by which aggre-
gated cytoplasmic proteins activate the UPR. The genetic
association between PERK and PSP suggests that this
UPR activation can influence the disease process, at least
in the case of PSP.
Surprisingly, we found that 10/14 normal controls over
50 years of age had at least minimal activation of pPERK
in the hippocampus. This is in contrast to previous studies
that report no pPERK staining in this region in normal
controls [26]. In these subjects, the degree of pPERK im-
munoreactivity correlated positively with both the degree
of htau immunoreactivity and age, but did not correlate
with amyloid pathology. The presence of at least some tau
pathology in the hippocampus of normal subjects is con-
sistent with work by others [41], and could potentially in-
dicate either pre-clinical AD or early neurofibrillary tangle
predominant dementia (NFTD). However, in the absence
of clinical symptoms, it is not possible to make either
diagnosis. These findings in normal controls are consis-
tent with the idea that the activation of the UPR is due to
the tau pathology and not the amyloid pathology.
We reported strong genetic evidence that EIF2AK3 geno-
types confer risk for PSP [10]. The strongest signal comes
from single nucleotide polymorphism (SNP) rs7571971 that
is within EIF2AK3. There are several non-synonymous cod-
ing polymorphisms in EIF2AK3 that track with risk and
EIF2AK3 appears to be the gene in this region involved in
PSP. However, another less likely but still plausible expla-
nation is that PSP risk in this region comes from a regula-
tory element that is intronic, within EIF2AK3, or in a close
by intergenic region and that this element controls expres-
sion of another gene. Also, the true PSP association could
be from nearby genes (e.g. FOXI3 or RPIA) though this is
less likely since the signal from SNPs in highlighting these
genes are not as significant as SNPs within EIF2AK3. The
work presented here clearly demonstrates that in PSP,
Table 4 Subject information
n Avg age of onset Avg age at death Avg disease duration % female Avg PMI
Normal – age-matched 15 N/A 71.7(8.4) N/A 46.7 12.7(8.5)
Normal – non age-matched 12 N/A 54.5(24.9) N/A 66.7 9.1(3.4)
Normal - total 27 N/A 64.0(19.4) N/A 56.7 11.1(6.9)
PSP 17 66.8(5.8) 73.7(5.2) 6. 7(2.2) 64.7 11.7(6.0)
AD 9 65.0(6.3) 75.8(5.1) 10. 8(3.4) 44.4 9.4(5.8)
There were no significant differences between groups for average age at death (ANOVA, p = 0.33), post-mortem interval (ANOVA, p = 0.54), average age of onset
(PSP and AD only, Student’s t-test, p = .45) or percent female (Chi Square, p = 0.89). Average disease duration for AD was significantly longer than for PSP
(Student’s t-test, p = 0.002). Standard deviations indicated inside parenthesis.
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regions where neurodegeneration occurs. Thus this func-
tional evidence along with the strength of the genetic evi-
dence indicates that EIF2AK3 and not an adjacent locus is
the gene that confers risk for PSP.
The SNP giving the strongest EIF2AK3 signal in the
PSP GWAS (rs7571971) is intragenic in intron 2. This
SNP is in strong disequilibrium with 3 EIF2AK3 exonic
SNPs which are non-synonymous. This relationship was
predicted using 1,000 Genomes data and confirmed here
in PSP subjects (Figure 7). These coding variants form
two common (A and B) and one rare haplotype (D). In
PSP subjects, the low risk allele [C] at rs7571971 com-
pletely correlates with haplotypes A and D while the high
risk rs7571971 allele [T] completely correlates with haplo-
type B (Figure 7).
Work in lymphoblastoid cell lines [31] with different
haplotypes show that expression of EIF2AK3 is not al-
tered by these haplotypes. However, when the PERK arm
of the UPR is activated by thapsigargin, PERK from
haplotype B homozygote cells is more active in phos-
phorylating eIF2α when compared to PERK from cells
homozygous for haplotype A. The haplotype that confers
high risk for PSP produces the more active form of PERK,
suggesting that activation of the UPR is pathogenic in PSP
and not a protective response. This is consistent with ob-
servations in prion protein induced neurodegeneration.
Moreno et al., showed that during prion replication, syn-
aptic failure and neuronal loss is temporally associated
with UPR activation and inhibition of translation. When
translation is restored using over-expression of GADD34
to dephosphorylate eIF2α, survival of infected animals is
prolonged. In contrast, when the UPR is activated usingTable 5 Anitbodies used
Antigen Epitope
Primary pPERK pThr981
peIF2α pSer51
AT8 pSer202/
Secondary goat α rabbit IgG biotin
goat α rabbit IgG AlexaFlu
goat α mouse IgG AlexaFlusalubrinal, survival is decreased [42]. Both observations
are consistent with activation of the PERK/eIF2α arm of
the UPR enhancing neurodegeneration, as proposed here
for PSP.
The two low risk haplotypes (haplotype A, Ser-Arg-Ser;
and haplotype B, Ser-Gln-Ser) differ only at the middle
amino acid, 166— this amino acid is unlikely to function-
ally influence PERK activation. The low and high risk
(Haplotype B, Cys-Gln-Cys) haplotypes differ at both posi-
tions 166 and 704, and one or both may influence PERK
activity. Amino acid 166 is on the portion of PERK that is
in the ER lumen and positioned where this protein senses
mis-folded proteins. Position 704 is on the cytoplasmic
side of PERK, a segment of the protein that is phosphory-
lated when activated and that has the active site for phos-
phorylating eIF2α. Additional work is needed to confirm
that haplotype B PERK is the more active protein and to
determine if mis-folded protein sensing or activation via
auto phosphorylation is affected.
Conclusions
The PERK protein and its downstream effector eIF2α are
phosphorylated in disease-affected regions in both PSP and
Alzheimer’s disease. A previous study using PSP samples
described UPR activation primarily in the hippocampus, a
brain region not affected in this disease [26]. In contrast,
we examined a large panel of brain areas (pons, medulla,
midbrain, hippocampus, frontal cortex, and folia of the
cerebellum) from PSP and AD cases as well as normal con-
trols to show that this activation is disease-specific in its
geographic distribution in the brain. In contrast to previous
reports, we also found UPR activation in the hippocampus
of a subset of our normal controls, a completely novelSource Dilution
Santa Cruz 1:4000
Sigma-Aldrich 1:2000
pThr205 Thermo Scientific 1:7500
Vector Labs 1:1000
or 488 Alexa 1:500
or 594 Alexa 1:500
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lated with both age and amount of tau pathology. This sug-
gests that tau and UPR activation are linked. We also
demonstrated a genetic association between an EIF2AK3
protein coding haplotype and PSP, indicating that variation
in the PERK protein affects PSP risk.
Methods
Human tissue
We obtained postmortem human pons, medulla, mid-
brain, frontal cortex, hippocampus, and cerebellum sam-
ples from the Center for Neurodegenerative Disease
Research (CNDR; University of Pennsylvania School of
Medicine, Philadelphia, PA) using the CNDR Integrated
Neurodegenerative Disease Database [33] and from the
Michigan Alzheimer’s Disease Research Center Brain Bank
(MADRC; University of Michigan, Ann Arbor, MI). We
chose PSP and AD cases for lack of co-morbid diagnoses
and availability of fixed tissue-- PSP and AD cases with
a secondary neuropathological diagnosis (NPDx; for in-
stance, PD) were excluded from the present study. All PSP
and AD cases were evaluated by a neurologist pre-mortem
and referred to the CNDR or MADRC brain donation pro-
grams, where a neuropathologist made a NPDx according
to established criteria [43,44]. Controls had no clinical his-
tory or postmortem diagnosis of a neurodegenerative dis-
ease. One control displayed a moderate amount of Lewy
body pathology in the medulla and another displayed a
mild amount of tau deposition in the midbrain (though
not in the substantia nigra). All control cases were free of
Lewy bodies in the hippocampus. We age-matched all
cases and controls (See Table 4 and Additional file 1: Table
S1 for demographic information). Tissue used for immu-
nohistochemical and immunofluorescence studies was
fixed in either ethanol (70%) or 10% neutral buffered for-
malin overnight and then processed for paraffin embed-
ding and 6 μm thick sections were generated as described
[45] using a Leitz 1512 microtome. The average age of PSP,
AD, and normal controls was approximately 75 years. Aver-
age disease duration for PSP patients was 6.7 years, while
the average duration for AD patients was 10.8 years. The
average post-mortem interval (PMI) for all cases was
10.2 hours (Table 4, and Additional file 1: Table S1). Pon-
tine sections included the locus coeruleus and surrounding
tegmentum, midbrain sections included the substantia
nigra, medulla sections included the olivary nucleus, hippo-
campal sections included the CA and dentate regions,
frontal cortex sections included both white and gray matter,
and cerebellar sections included the folia.
Immunohistochemistry
Immunohistochemistry was performed as previously de-
scribed [46,47]. We deparaffinized brain sections on slides
using xylene (Mallinckrodt Baker Inc., Phillipsburg, NJ),and then hydrated them through a series of ethanol washes,
and quenched endogenous peroxidases by immersing sec-
tions in a mixture of hydrogen peroxide and methanol. Fol-
lowing a wash in running water, we performed antigen
retrieval by microwaving sections immersed in citrate buf-
fer (Thermo Shandon Limited, Astmoor, WA). We then
washed sections in 0.1 M Tris (pH 7.6; Fisher Scientific),
blocked in 0.1 M Tris (pH 7.6)/2% fetal bovine serum
(FBS), and applied primary antibody (incubated overnight
at 4°). This wash/block procedure was identical for second-
ary antibody application, with an incubation time of one hr.
Following another wash, we applied avidin/biotin complex
(Vector Labs) to each section and incubated the sections
for one hr. Finally, we developed sections with DAB
chromagen (Biogenex), counterstained with hematoxylin,
dehydrated through a series of ethanol and xylene washes.
Cover slips were sealed with Cytoseal (Richard Allen Scien-
tific, Kalamazoo, MI). Antibodies used are listed in Table 5.
Immunofluorescence (IF)
We deparaffinized, hydrated, quenched, and performed
antigen retrieval on slide-mounted sections as described
above. We then blocked sections in 0.1 M Tris/2% FBS,
and applied mouse and rabbit primary antibodies (di-
luted in 0.1 M Tris/2% FBS). Primary antibody incuba-
tion time was 2 hr at room temperature. Following a
wash in 0.1 M Tris and transfer to a “dark” chamber, we
applied secondary antibodies (goat-anti-mouse and goat-
anti-rabbit; Vector Labs) and let sections incubate for
another two hr at room temperature. We then washed the
sections again and applied 0.3% Sudan Black in 70% etha-
nol [48] for five min to quench endogenous lipofuscin
related fluorophores. After another wash, the sections
were coverslipped using Vectashield (with DAPI; Vector
Labs; [49]).
Slide scoring and analysis
pPERK and peIF2 antibodies both stained cells in a char-
acteristic punctate pattern (Figures 1a and 2a; [25,27]).
We scored each tissue section for pPERK or peIF2α IHC
staining according to the following scale: negative (−): no
cells stained, rare (R): 1–3 cells stained, +: 4–20 cells
stained, ++: 20+ cells stained, could have diffuse distri-
bution of stained cells, may have high density of stained
cells in some fields of the section, +++: high density of
stained cells in almost every field of the section. A sec-
ond rater confirmed scores in 20% of randomly selected
slides (see Online Resource Figure 1). For double IF of
hyperphosphorylated tau (htau) and pPERK, we visualized
and photographed 10 fields per section and manually
counted the number of htau positive cells, the number of
pPERK positive cells, and the number of cells positive for
both pPERK and htau. We scored all sections blind to dis-
ease group on an Olympus CHBS microscope (IHC) or an
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with BF/DF/DIC/Polarized Light and a SPOT RT Color
digital microscope camera (IF).Statistical analysis
We used Spearman correlations to examine correla-
tions between level of tau pathology vs. pPERK stain-
ing and age vs. pPERK staining, Fisher’s exact test to
examine association between disease condition and
pPERK/peIF2α staining, Chi Square to examine sex
distribution among disease/normal groups, ANOVA
to examine the mean difference among disease/nor-
mal groups for average age at death and post-mortem
interval, and a Student’s t-test to examine the mean
difference between disease groups for average age of
onset. All statistical analyses were two-sided. Statis-
tical significance was set at the 0.05 level unless
otherwise indicated.Analysis of linkage disequilibrium around rs7571971
In a recent GWAS for PSP risk loci [10], a significant
association was established between PSP risk and
rs7571971. This SNP falls in an intron of EIF2AK3, the
gene encoding PERK. While it is reasonable to assume
the SNP somehow affects risk for PSP by affecting
expression of EIF2AK3, it remains to be proven. To
garner genetic evidence for this hypothesis, we first eval-
uated the pattern LD in sequence data from the 1000
Genomes project [50] and pairwise LD evaluated using
SNAP (Suite of Nucleotide Analysis Programs, [51]).
Based on these results, we genotyped 1043 PSP patients
using TaqMan SNP Genotyping Assays (Applied
Biosystems, Foster City, CA) for the following four
SNPs: rs7571971, rs867529 (S136C), rs1805165 (S704A),
and rs13045 (R166Q). All cases were autopsied and had
a neuropathologic diagnosis of PSP [52]. Genotyping
was done according to manufacturer’s protocol. PCR
conditions were as follows: 95°C for 10 minutes, then
50 cycles of 92°C for 15 seconds, 60°C for 1 minute,
4°C for 2 minutes. Genotypes were visualized and
called using a 7900HT Fast Real Time PCR System
and the allelic discrimination function of Sequence
Detection System V.2.4 (Applied Biosystems, Foster
City, CA). Finally, we phased the resulting four-SNP
genotypes using eHap software [53], which provides
maximum likelihood estimates of haplotype frequen-
cies. Approval for the use of de-identified patient
samples was approved by the University of Pennsylva-
nia Institutional Review Board (IRB); sample and
demographic information collection at each participat-
ing site was approved by institution-specific IRB. In-
formed consent was obtained for all samples collected
in a clinical setting.Additional file
Additional file 1: Figure S1. Scoring system examples. Representative
fields from brain areas that scored “-“ (negative), “R” (rare), “+” (mild
staining), “++” (moderate staining), and “+++” (heavy staining), along
with scoring criteria. Table S1. Individual Case Information.
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